Indications
Plecanatide is approved for the treatment of chronic idiopathic constipation (CIC) in adults. 1, 2 It is also being evaluated for the treatment of irritable bowel syndrome with constipation (IBS-C). 3, 4, 5 Constipation is characterized by dysfunction of colonic motility and the defecation process. CIC is a functional type of constipation. Constipation is defined as a symptom-based disorder characterized by infrequent stools and/or difficult stool passage; it tends to be more common in females, older patients, and those of lower socioeconomic status. 6, 7 Linaclotide is approved for the treatment of CIC or IBS-C in adults. 8 Other drugs used in the treatment of these conditions include laxatives, prokinetic agents, serotonergic agents, prosecretory agents (including linaclotide and plecanatide), and bile acid modulators. 9, 10 Based on its pharmacology, plecanatide may also be effective in the treatment of ulcerative colitis. 11 
Clinical Pharmacology
Plecanatide is a uroguanylin analog. Uroguanylin and guanylin are natriuretic peptides involved in the maintenance of normal bowel movements. Uroguanylin and guanylin are agonists of guanylate cyclase C (GC-C) receptors in the gastrointestinal (GI) tract; however, their binding affinity may be affected by pH within the GI tract. Activation of GC-C receptors in the GI tract stimulates intracellular production of cyclic guanosine monophosphate (cGMP), which then activates cystic fibrosis transmembrane conductance regulator (CFTR) and cGMP-dependent protein kinase G-II. The activation of both CFTR and cGMP-dependent protein kinase G-II produces an efflux of chloride ions from enterocytes lining the GI tract, resulting in an efflux of water into the intestinal lumen. 2, 12, 13, 14, 15 Plecanatide is a peptide containing 16 amino acids that is structurally similar to uroguanylin. The structural difference between plecanatide and uroguanylin is a single amino acid (ie, replacement of the penultimate aspartate at the N-terminus with glutamate in plecanatide). 9, 13, 14, 15 Plecanatide's effect on the GI tract is expected to be similar to that of uroguanylin. 14, 15 Linaclotide, also a GC-C agonist, may have less variation in its binding affinity to GC-C receptors along the longitudinal axis of the GI tract because of its relative insensitivity to changes in pH between 5 and 8. 8, 12 The clinical significance of this difference in binding affinity between plecanatide and linaclotide relative to pH has not been determined.
Pharmacokinetics
Plecanatide does not appear to be absorbed from the GI tract; no detectable plasma concentrations were observed after single oral doses of plecanatide ranging from 0.1 to 48.6 mg. 2, 14, 16 Linaclotide is minimally absorbed, with low systemic availability following oral administration. 8 Plecanatide is metabolized in the GI tract to an active metabolite. Both plecanatide and its active metabolite are proteolytically degraded within the intestinal lumen to smaller peptides and naturally occurring amino acids. 2 Comments: Initial management of symptomatic constipation is dietary modification, which may include fiber and fluid supplements. Osmotic laxatives are recommended for the treatment of chorionic constipation. Stimulant laxatives are recommended for short-term, second-line treatment of chronic constipation. When dietary modifications as well as osmotic and stimulant laxative therapy have failed, linaclotide and lubiprostone may be considered. Surgery may be appropriate in certain refractory cases. Plecanatide is mentioned in this guideline as an investigational agent.
Comparative Efficacy

Studies. Drug: Plecanatide versus placebo
Reference: Miner PB, et al, 2013 17, 18 Study Design: Randomized, double-blind, multicenter study Study Funding: Synergy Pharmaceuticals Patients: 951 patients with CIC. Patients had to meet modified Rome III criteria for CIC diagnosis and have fewer than 3 complete spontaneous bowel movements (CSBMs) per week. Exclusion criteria were loose or watery stool in the absence of laxative use for more than 25% of bowel movements during 3 months prior to screening or during the 14-day pretreatment period; Rome III IBS-C diagnosis; active peptic ulcer disease not adequately treated; history of cathartic colon, laxative or enema abuse, or ischemic colitis; fecal impaction within 3 months of screening; disease or condition associated with constipation; structural abnormality of the GI tract or gastric bypass surgery; pelvic floor dysfunction; pseudo-obstruction; active infectious gastritis; diverticulitis; anal fissures or disease/condition that can affect GI motility or defecation or that is associated with abdominal pain; unexplained GI bleeding, iron deficiency anemia, weight loss, or systemic signs of infection or colitis; and major surgery within 60 days of screening. Of the 951 patients enrolled, 946 received at least 1 dose of the study medication and had at least 1 postdose efficacy assessment. Plecanatide-treated patients had a mean age of 47 years, and 86.5% were female; demographics of the placebo group were similar.
Intervention: Patients were randomized to receive placebo or plecanatide 0.3 mg, 1 mg, or 3 mg once daily for 12 treatment weeks.
Results
Primary End Point(s)
• • Proportion of weekly responders, defined as those having at least 3 CSBMs per week and an increase of at least 1 CSBM per week from baseline, was 11.5% with placebo (P = NS), 19% with plecanatide 0.3 mg (P < .05), 17.2% with plecanatide 1 mg (P = NS), and 21.5% with plecanatide 3 mg (P < .01). • • Proportion of durable overall responders, defined as patients who were weekly responders for at least 9 of 12 treatment weeks, including 3 of the last 4 treatment weeks, was 10.7% with placebo (P = NS), 18.6% with plecanatide 0.3 mg (P < .05), 16.8% with plecanatide 1 mg (P = NS), and 19% with plecanatide 3 mg (P < .01). The number needed to treat (NNT) for durable overall CSBM response over 12 weeks of therapy was 12.1 with plecanatide 3 mg.
Secondary End Point(s)
• • Change in frequency of spontaneous bowel movements (SBMs) and CSBMs per week from baseline occurred within the first week and were maintained through week 12 with plecanatide 3 mg. Weekly CSBMs increased by 1 or more from baseline over 12 weeks in 36.8% of patients with placebo (P = NS), 42.6% with plecanatide 0.3 mg (P = NS), 50% with plecanatide 1 mg (P < .01), and 52.3% with plecanatide 3 mg (P < .001).
Comments: This phase 2b/3 dose-ranging study was designed to assess the efficacy and safety of plecanatide in the treatment of CIC. Electronic diaries were used to track SBMs, CSBMs, and symptoms; missing diary data were imputed using mean data as replacement. The study used a modified intention-to-treat (mITT) population for analysis.
Limitations: Study results are only available as a published abstract.
Reference: Miner PB, et al, 2016 (Study-00) 19, 20 Study Design: Randomized, double-blind, multicenter study Study Funding: Synergy Pharmaceuticals Patients: 1346 adults with CIC. Patients had to meet modified Rome III criteria for CIC diagnosis and had to have experienced symptoms for at least 3 months, with symptom onset at least 6 months prior to diagnosis. Exclusion criteria were loose or watery stool in the absence of laxative use for more than 25% of bowel movements during 3 months prior to screening or during the 14-day pretreatment period; active peptic ulcer disease, diabetes, or hypertension not adequately treated; history of cathartic colon, laxative or enema abuse, or ischemic colitis; fecal impaction within 3 months of screening; disease or condition associated with constipation; structural abnormality of the GI tract or gastric bypass surgery; pelvic floor dysfunction; pseudo-obstruction; active infectious gastritis; diverticulitis; anal fissures or disease/condition that can affect GI motility or defecation or that is associated with abdominal pain; unexplained GI bleeding, iron deficiency anemia, weight loss, or systemic signs of infection or colitis; and participation in a previous plecanatide clinical trial.
Intervention: Patients were randomized (1:1:1) to receive placebo or plecanatide 3 mg or 6 mg once daily for 12 treatment weeks.
Results
Primary End Point(s)
• • Proportion of durable overall responders, defined as patients who were weekly responders (3 or more CSBMs and an increase of 1 or more CSBM from baseline) for at least 9 of 12 treatment weeks, including 3 of the last 4 weeks, was 10.2% with placebo, 21% with plecanatide 3 mg, and 19.5% with plecanatide 6 mg (P < .001 vs placebo for both). The NNT for durable overall CSBM response over 12 weeks of therapy was 9.3 with plecanatide 3 mg and 10.8 with plecanatide 6 mg.
Secondary End Point(s) • • Changes in the frequency of SBMs and CSBMs per
week from baseline occurred within the first week and were maintained through week 12. SBMs increased from baseline at week 12 by 1.4 with placebo, 3.3 with plecanatide 3 mg, and 3.2 with plecanatide 6 mg (P < .001 vs placebo for both). CSBMs increased from baseline by 1.2 per week with placebo, by 2.5 per week with plecanatide 3 mg, and by 2.2 per week with plecanatide 6 mg (P < .001 vs placebo for both).
Comments: This phase 3 study was designed to assess the efficacy and safety of plecanatide in the treatment of CIC. Electronic diaries were used to track SBMs, CSBMs, and symptoms. The study used an mITT population for analysis and was conducted in the United States and Canada.
Reference: Miner PB, et al, 2016 (Study-03) 21, 22 Study Design: Randomized, double-blind, multicenter study Study Funding: Synergy Pharmaceuticals Patients: 1337 adults with CIC. Patients had to meet modified Rome III criteria for CIC diagnosis and had to have experienced symptoms for at least 3 months, with symptom onset at least 6 months prior to diagnosis.
Results
Primary End Point(s)
• • Proportion of durable overall responders, defined as patients who were weekly responders (3 or more CSBMs and an increase of 1 or more CSBM from baseline) for at least 9 of 12 treatment weeks, including 3 of the last 4 weeks, increased by 12.8% with placebo, 20.1% with plecanatide 3 mg, and 20% with plecanatide 6 mg (P = .004 vs placebo for both). The NNT for durable overall CSBM response over 12 weeks of therapy was 13.7 with plecanatide 3 mg and 13.9 with plecanatide 6 mg.
Secondary End Point(s) • • Changes in the frequency of SBMs and CSBMs per
week from baseline occurred within the first week and were maintained through week 12. SBMs increased from baseline at week 12 by 1.8 with placebo, 3.2 with plecanatide 3 mg, and 3.2 with plecanatide 6 mg (P < .001 vs placebo for both). CSBMs increased from baseline by 1.4 per week with placebo, by 2.3 per week with plecanatide 3 mg, and by 2.2 per week with plecanatide 6 mg (P < .001 vs placebo for both).
Comments:
This study used the same design as Study-00 and was conducted only in the United States. 19, 22 Pooled analysis of Study-00 and Study-03 demonstrated improvements in Bristol Stool Form Scale scores, Patient Global Assessments of constipation severity, treatment satisfaction scores, and treatment continuation scores with both doses of plecanatide compared with placebo. 23, 24 Patients from these 2 studies were eligible to enroll in a multicenter, open-label, 52-week safety and tolerability study of plecanatide. 25 Limitations: Study results are only available as a published abstract.
Contraindications, Warnings, and Precautions
Contraindications
Plecanatide is contraindicated in patients younger than 6 years due to the risk of serious dehydration, and in patients with known or suspected mechanical GI obstruction. 2 Linaclotide has similar contraindications. 8 Although not stated in the prescribing information, a potential contraindication is hypersensitivity to plecanatide or any of its inactive ingredients (magnesium stearate and microcrystalline cellulose). 2
Warnings and Precautions
According to the boxed warning for plecanatide, use in children 6 years to younger than 18 years is not recommended; death from dehydration occurred in young juvenile mice administered a single dose of plecanatide in nonclinical studies. 2 The safety and effectiveness of plecanatide in patients younger than 18 years have not been determined; use in this age group should be avoided. 2 Clinical studies of plecanatide did not include sufficient numbers of patients 65 years and older to determine whether they respond differently from younger patients. In general, dose selection in elderly patients should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. 2 Diarrhea can occur with plecanatide therapy. Severe diarrhea was reported in 0.6% of patients in clinical trials. If severe diarrhea occurs, suspend plecanatide therapy and start rehydration therapy. 2 Because plecanatide and its active metabolites are not well absorbed following oral administration, maternal use is not expected to result in fetal exposure to plecanatide; however, evidence in humans is insufficient to support this conclusion. In animal development studies, administration of plecanatide to pregnant mice and rabbits at doses higher than the recommended human dosage showed no effects on embryofetal development. 2 There is no information regarding the presence of plecanatide in human milk or its effects on milk production or breastfeeding infants. 2 The warnings and precautions for linaclotide are similar to those for plecanatide. 8
Adverse Reactions
In clinical trials, diarrhea occurred in 5% of plecanatidetreated patients compared with 1% of placebo patients and was the main reason for discontinuation of plecanatide therapy (2% of patients in the plecanatide group vs 0.5% of the placebo group). The majority of cases of diarrhea occurred within 4 weeks of starting plecanatide therapy. 2 In linaclotide clinical trials, diarrhea occurred in 16% of patients treated with linaclotide compared with 5% of placebo patients. The main reasons for discontinuation of linaclotide therapy were diarrhea (5% vs less than 1% of the placebo group) and abdominal pain (1% vs less than 1% of the placebo group). 8 Other adverse reactions reported with plecanatide included sinusitis, upper respiratory tract infection, abdominal distension, flatulence, abdominal tenderness, and increased liver biochemical tests (2 patients with alanine aminotransferase [ALT] levels greater than 5 to 15 times the upper limit of normal, and 3 patients with aspartate aminotransferase [AST] levels greater than 5 times the upper limit of normal). 2
Drug Interactions
No clinically important drug-drug interactions have been reported with plecanatide. In vitro tests show that plecanatide and its active metabolite are neither substrates nor inhibitors of the transporters P-glycoprotein (P-gp) or breast cancer resistance protein. 2 No clinically important drug-drug interactions have been reported with linaclotide, and linaclotide has not been shown to interact with the cytochrome P450 enzyme system or with P-gp. 8
Recommended Monitoring
Patients who develop severe diarrhea should be assessed for electrolyte abnormalities and the need for rehydration therapy.
Dosing
The recommended plecanatide dosage is 3 mg orally once daily with or without food. 2 A dosage of 6 mg was used in clinical studies but is not recommended due to a lack of additional benefit and a greater incidence of adverse reactions. 2 Plecanatide tablets should be swallowed whole. If the patient has difficulty swallowing, the tablet can be crushed and administered orally in applesauce or with water; the entire mixture should be immediately consumed after mixing. If the patient has a nasogastric or gastric feeding tube, the tablet can be crushed and administered with water through the tube immediately after mixing. Prior to administration, the feeding tube should be flushed with 30 mL of water using an appropriate syringe; after administration of the water/drug mixture, the feeding tube should be flushed with at least 10 mL of water. 2 The recommended dosage of linaclotide is 145 mcg orally once daily on an empty stomach, at least 30 minutes prior to the first meal of the day. The capsules should not be crushed or chewed. If the patient has difficulty swallowing, the capsule can be opened and mixed with applesauce or water. A water/linaclotide mixture can be administered through a nasogastric or gastric feeding tube. 8
Product Availability
The New Drug Application for plecanatide was filed with the US Food and Drug Administration in 2016, and was approved in January 2017. 1, 5 Plecanatide is available as a 3-mg tablet. It is supplied in bottles of 30 and in child-resistant, aluminum foil unit-dose blister packs of 30. 2 It should be stored in a dry place at 20°C to 25°C (68°F-77°F), with excursions permitted to 15°C to 30°C (59°F-86°F). The tablets should be protected from moisture and stored in the original bottle with the desiccant; they should not be subdivided or repackaged. 2
Drug Safety/REMS
No Risk Evaluation and Mitigation Strategy (REMS) is required for plecanatide or linaclotide. 1, 2, 8 
Conclusion
Plecanatide is approved for the treatment of CIC in adults. In placebo-controlled studies, plecanatide improved the frequency of both SBMs and CSBMs. Head-to-head comparison studies with linaclotide have not been conducted. Although linaclotide is approved for both CIC and IBS-C, plecanatide is only approved for CIC. Outcome data to evaluate the impact on health care costs (eg, changes in frequency of clinic visits, frequency of acute exacerbations) are not available.
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